One such treatment gaining popularity is Ozempic, a GLP-1 receptor agonist designed to aid in both diabetes management and weight loss
This matters because lean soft tissue loss comprised 26% to 40% of weight loss in recent trials of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists
Both formulations contain tirzepatide as their active component, which works by activating GLP-1 and GIP receptors in the brain to reduce hunger signals and increase satiety
Tools to track your progress: Use our GLP-1 Companion to easily track your weight, protein intake, and health metrics in real-time
If you think of it as a short-term tool, then what will likely happen is you will lose the weight, and once you stop taking the medicine, you will regain it
TAK1 safeguards endothelial cells from gut microbes and inflammation